Asia Pacific Alzheimer’s Therapeutics Market to Exhibit 7.9% CAGR 2014-2021

Published on : Apr 12, 2016

ALBANY, New York, April 12, 2016: The Asia Pacific market for Alzheimer’s therapeutics has been analyzed in a detailed market research report recently added to the portfolio of The report is titled “Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies.”

The report states that the Asia Pacific market for Alzheimer’s disease therapeutics will expand at a healthy 7.9% CAGR between 2014 and 2021 and rise to a valuation of US$5.1 bn in 2021, from a value of US$3 bn in 2014. The market for Alzheimer’s disease therapeutics has been assessed for four countries in Asia Pacific: India, Australia, China, and Japan.

Alzheimer’s disease (AD) is a progressive and irreversible neurodegenerative condition leading to issues such as memory loss, cognitive impairment, and overall functional decline of the brain’s abilities to undertake several tasks. Symptoms of Alzheimer’s disease appear in varying frequencies in patients and begin occurring typically in the mid-sixties.

Pathological characteristics of AD include histopathological changes in the human brain. Almost all cases of Alzheimer’s begin with the occurrence of mild cognitive impairment (MCI), a state between normal cognition and dementia, wherein changes in the cognitive abilities of the brain, such as thinking and memory, are affected. However, not all cases of MCI develop into Alzheimer’s disease.

The report gives a thorough account of the key marketed products for the treatment of Alzheimer’s disease, major pipeline products, and a detailed analysis of clinical trials that are assessing major pipeline products.

The report states that though the attrition rates of Alzheimer’s disease clinical trials are as high as 94%, the number of drugs in the Asia Pacific Alzheimer’s disease therapeutics market is substantial, at 559. The majority of drugs in the pipeline are new, and there are only five generic and seven repositioned drugs.

The report gives an expansive account of key elements of the market, furnishing details pertaining to the chief classes of drugs in the market and the dominant drug types in current scenario, technological advances and entry of new approved therapies in the market, and analysis of clinical trial results of late-stage pipeline therapies.

The report also gives detailed data pertaining to the pipeline, including details regarding the key molecule types, molecular targets, factual data regarding the molecules that appear most frequently in the pipeline, and the failure rates for individual phases of drug development.

The report gives a detailed account of the key drivers and restraints of the Asia Pacific Alzheimer’s disease therapeutics market and presents an analysis of the potential impact of these factors on the development of the market over the report’s forecast period.

The report helps the reader understand the competitive landscape of the Asia Pacific Alzheimer’s disease therapeutics market by providing a thorough examination of disease diagnosis, pathogenesis, prognosis, and current course of treatment used for treating AD.

Details such as the number of licensing deals and co-development deals pertaining to Alzheimer’s disease therapeutic products since 2006, the regions exhibiting the highest deal activity, major trends in deal completion, and deal conditions have also been included in the report.

About MarketResearchHub

MarketResearchHub is the most comprehensive market intelligence repository, supporting clients’ needs with over 100,000 reports, company profiles, data books, and regional market profiles. We also offer consulting support for custom market research needs.’s document database is updated by the hour, which means that our customers always have access to fresh data spanning over 300 industries. From Fortune 500 companies to SMEs, we have built a veritable reputation for fulfilling the most exacting market research needs.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top